Form 4: Acrivon Therapeutics Officer Sells Shares

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc., reported a transaction involving the sale of common stock.

Summary

• Katharine Peterson, Chief Accounting Officer at Acrivon Therapeutics, Inc., engaged in a transaction on May 14, 2026.
• This transaction involved the sale of 99 shares of common stock at a price of $1.92 per share.
• The shares were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following this transaction, Ms. Peterson beneficially owns 3,907 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a standard tax withholding event and not indicative of a change in the insider's view of the company's prospects.

Negatives

• A company officer sold shares, which could be perceived negatively by the market, although it was for tax withholding purposes.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions and do not typically provide strategic insights. The nature of this transaction, a tax withholding, is a common occurrence upon vesting of equity awards.

Stakeholder Impact

• Shareholders: The sale of shares by an officer, even for tax purposes, may lead to short-term market perception shifts, though the underlying beneficial ownership remains largely unchanged.

Key Dates

Keywords

Form 4, SEC Filing, Acrivon Therapeutics, ACRV, Stock Transaction, Beneficial Ownership, Katharine Peterson, Chief Accounting Officer, Tax Withholding